l

Diagnostic Radiopharmaceuticals: A Sustainable Path to the Improvement of Patient Care




l

One Bite from the Apple, One Bite from the Orange in the PRECISE-MDT Study




l

Reply: One Bite from the Apple, One Bite from the Orange in the PRECISE-MDT Study and Limitations of Retrospective Study Design and Potential Bias in the PRECISE-MDT Study




l

SNMMI Procedure Standard/EANM Practice Guideline for Brain [18F]FDG PET Imaging, Version 2.0

PREAMBLE

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific and professional organization founded in 1954 to promote the science, technology, and practical application of nuclear medicine. The European Association of Nuclear Medicine (EANM) is a professional nonprofit medical association that facilitates communication worldwide between individuals pursuing clinical and research excellence in nuclear medicine. The EANM was founded in 1985. The EANM was founded in 1985. SNMMI and EANM members are physicians, technologists, and scientists specializing in the research and practice of nuclear medicine.

The SNMMI and EANM will periodically define new guidelines for nuclear medicine practice to help advance the science of nuclear medicine and to improve the quality of service to patients throughout the world. Existing practice guidelines will be reviewed for revision or renewal, as appropriate, on their fifth anniversary or sooner, if indicated.

Each practice guideline, representing a policy statement by the SNMMI/EANM, has undergone a thorough consensus process in which it has been subjected to extensive review. The SNMMI and EANM recognize that the safe and effective use of diagnostic nuclear medicine imaging requires specific training, skills, and techniques, as described in each document. Reproduction or modification of the published practice guideline by those entities not providing these services is not authorized.

These guidelines are an educational tool designed to assist practitioners in providing appropriate care for patients. They are not inflexible rules or requirements of practice and are not intended, nor should they be used, to establish a legal standard of care. For these reasons and those set forth below, both the SNMMI and the EANM caution against the use of these guidelines in litigation in which the clinical decisions of a practitioner are called into question.

The ultimate judgment regarding the propriety of any specific procedure or course of action must be made by the physician or medical physicist in light of all the circumstances presented. Thus, there is no implication that an approach differing from the guidelines, standing alone, is below the standard of care. To the contrary, a conscientious practitioner may responsibly adopt a course of action different from that set forth in the guidelines when, in the reasonable judgment of the practitioner, such course of action is indicated by the condition of the patient, limitations of available resources, or advances in knowledge or technology subsequent to publication of the guidelines.

The practice of medicine includes both the art and the science of the prevention, diagnosis, alleviation, and treatment of disease. The variety and complexity of human conditions make it impossible to always reach the most appropriate diagnosis or to predict with certainty a particular response to treatment.

Therefore, it should be recognized that adherence to these guidelines will not ensure an accurate diagnosis or a successful outcome. All that should be expected is that the practitioner will follow a reasonable course of action based on current knowledge, available resources, and the needs of the patient to deliver effective and safe medical care. The sole purpose of these guidelines is to assist practitioners in achieving this objective.




l

Limitations of Retrospective Study Design and Potential Bias in the PRECISE-MDT Study




l

Improved Localization of Insulinomas Using 68Ga-NODAGA-Exendin-4 PET/CT

Visual Abstract




l

MIRD Pamphlet No. 31: MIRDcell V4--Artificial Intelligence Tools to Formulate Optimized Radiopharmaceutical Cocktails for Therapy

Visual Abstract




l

Modeling PET Data Acquired During Nonsteady Conditions: What If Brain Conditions Change During the Scan?

Researchers use dynamic PET imaging with target-selective tracer molecules to probe molecular processes. Kinetic models have been developed to describe these processes. The models are typically fitted to the measured PET data with the assumption that the brain is in a steady-state condition for the duration of the scan. The end results are quantitative parameters that characterize the molecular processes. The most common kinetic modeling endpoints are estimates of volume of distribution or the binding potential of a tracer. If the steady state is violated during the scanning period, the standard kinetic models may not apply. To address this issue, time-variant kinetic models have been developed for the characterization of dynamic PET data acquired while significant changes (e.g., short-lived neurotransmitter changes) are occurring in brain processes. These models are intended to extract a transient signal from data. This work in the PET field dates back at least to the 1990s. As interest has grown in imaging nonsteady events, development and refinement of time-variant models has accelerated. These new models, which we classify as belonging to the first, second, or third generation according to their innovation, have used the latest progress in mathematics, image processing, artificial intelligence, and statistics to improve the sensitivity and performance of the earliest practical time-variant models to detect and describe nonsteady phenomena. This review provides a detailed overview of the history of time-variant models in PET. It puts key advancements in the field into historical and scientific context. The sum total of the methods is an ongoing attempt to better understand the nature and implications of neurotransmitter fluctuations and other brief neurochemical phenomena.




l

Head-to-Head Comparison of [68Ga]Ga-NOTA-RM26 and [18F]FDG PET/CT in Patients with Gastrointestinal Stromal Tumors: A Prospective Study

Visual Abstract




l

[18F]F-AraG Uptake in Vertebral Bone Marrow May Predict Survival in Patients with Non-Small Cell Lung Cancer Treated with Anti-PD-(L)1 Immunotherapy

Visual Abstract




l

Intraarterial Administration of Peptide Receptor Radionuclide Therapy in Patients with Advanced Meningioma: Initial Safety and Efficacy

Visual Abstract




l

Comparison of Posttherapy 4- and 24-Hour [177Lu]Lu-PSMA SPECT/CT and Pretherapy PSMA PET/CT in Assessment of Disease in Men with Metastatic Castration-Resistant Prostate Cancer

Visual Abstract




l

Comparison Between Brain and Cerebellar Autoradiography Using [18F]Flortaucipir, [18F]MK6240, and [18F]PI2620 in Postmortem Human Brain Tissue

Visual Abstract




l

Outcomes for Patients with Metastatic Castration-Resistant Prostate Cancer and Liver Metastasis Receiving [177Lu]Lu-PSMA-617

Visual Abstract




l

Clinical, Pathologic, and Imaging Variables Associated with Prostate Cancer Detection by PSMA PET/CT and Multiparametric MRI

Visual Abstract




l

CT Enhancement of a Nasal Leech After Thrombectomy




l

FAP and PSMA Expression by Immunohistochemistry and PET Imaging in Castration-Resistant Prostate Cancer: A Translational Pilot Study

Visual Abstract




l

Oncologist, Business Leader, and Investor Arie S. Belldegrun Discusses a Career in Innovative Medical Entrepreneurship: A Conversation with Ken Herrmann and Johannes Czernin




l

Kinetic Analysis and Metabolism of Poly(Adenosine Diphosphate-Ribose) Polymerase-1-Targeted 18F-Fluorthanatrace PET in Breast Cancer

Visual Abstract




l

[18F]FDG and [68Ga]Ga-FAPI-04-Directed Imaging for Outcome Prediction in Patients with High-Grade Neuroendocrine Neoplasms

Visual Abstract




l

Feasibility, Tolerability, and Preliminary Clinical Response of Fractionated Radiopharmaceutical Therapy with 213Bi-FAPI-46: Pilot Experience in Patients with End-Stage, Progressive Metastatic Tumors

Visual Abstract




l

Performance Characteristics of a New Generation 148-cm Axial Field-of-View uMI Panorama GS PET/CT System with Extended NEMA NU 2-2018 and EARL Standards

Visual Abstract




l

SPECT/CT in Early Response Assessment of Patients with Metastatic Castration-Resistant Prostate Cancer Receiving 177Lu-PSMA-617

Visual Abstract




l

CD70-Targeted Immuno-PET/CT Imaging of Clear Cell Renal Cell Carcinoma: A Translational Study

Visual Abstract




l

Feasibility of 177Lu-PSMA Administration as Outpatient Procedure for Prostate Cancer




l

International Metabolic Prognostic Index Is Superior to Other Metabolic Tumor Volume-Based Prognostication Methods in a Real-Life Cohort of Diffuse Large B-Cell Lymphoma

Visual Abstract




l

Changed Regulation Enables Pragmatic Solution for Cancer Patients




l

SophosAI team presents three papers on AI applied to cybersecurity at CAMLIS

On October 24 and 25, SophosAI presents ideas on how to use models large and small—and defend against malignant ones.




l

Sophos Firewall hardening best practices

Make the most of your Sophos Firewall.




l

Pacific Rim timeline: Information for defenders from a braid of interlocking attack campaigns

Sophos X-Ops unveils five-year investigation tracking China-based groups targeting perimeter devices




l

Digital Detritus: The engine of Pacific Rim and a call to the industry for action

Decades of obsolete and unpatched hardware and software endanger us all




l

Pacific Rim: Learning to eat soup with a knife

What our incident responders know from five years of fighting an octopus




l

From the frontlines: Our CISO’s view of Pacific Rim

On beyond “Detect and Respond” and “Secure by Design”






l

VEEAM exploit seen used again with a new ransomware: “Frag”

Last month, Sophos X-Ops reported several MDR cases where threat actors exploited a vulnerability in Veeam backup servers. We continue to track the activities of this threat cluster, which recently included deployment of a new ransomware. The vulnerability, CVE-2024-40711, was used as part of a threat activity cluster we named STAC 5881. Attacks leveraged compromised […]




l

Re: Voluntary assisted death: how to ensure access and safety




l

"Questioning the Quantifiable: Are We Measuring What Matters in Heart Failure Care?"




l

Overdose crisis: more common sense and less ideology




l

Addressing Climate Catastrophe Concerns in Asthma Medication Delivery: Rethinking Inhaler Use for Environmental and Clinical Efficacy




l

Re: Scandal of “newborn gang” that put profits ahead of babies’ lives rocks Turkey’s health system




l

Re: Scandal of “newborn gang” that put profits ahead of babies’ lives rocks Turkey’s health system




l

Re: Scandal of “newborn gang” that put profits ahead of babies’ lives rocks Turkey’s health system




l

Re: Scandal of “newborn gang” that put profits ahead of babies’ lives rocks Turkey’s health system




l

Re: Decompression alone or with fusion for degenerative lumbar spondylolisthesis (Nordsten-DS): five year follow-up of a randomised, multicentre, non-inferiority trial




l

A Comprehensive Gender-related Secretome of Plasmodium berghei Sexual Stages

Felicia Grasso
Dec 1, 2020; 19:1986-1996
Research




l

Citrus Vascular Proteomics Highlights the Role of Peroxidases and Serine Proteases during Huanglongbing Disease Progression

Jessica Y. Franco
Dec 1, 2020; 19:1936-1951
Research




l

Global lysine acetylation and 2-hydroxyisobutyrylation reveal the metabolism conversion mechanism in Giardia lamblia

Wenhe Zhu
Dec 29, 2020; 0:RA120.002353v1-mcp.RA120.002353
Research




l

Novel Proteomic Profiling of Epididymal Extracellular Vesicles in the Domestic Cat Reveals Proteins Related to Sequential Sperm Maturation with Differences Observed between Normospermic and Teratospermic Individuals

Tricia Rowlison
Dec 1, 2020; 19:2090-2103
Research




l

Separation and identification of permethylated glycan isomers by reversed phase nanoLC-NSI-MS

Simone Kurz
Dec 29, 2020; 0:RA120.002266v1-mcp.RA120.002266
Research